Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.55 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL6313707 | 0.83 | ADORA1 (0.50) | IGF1RPIK3CAS1PR1 | |
| SCHEMBL6319164 | 0.82 | PIK3CA (0.58) | IGF1RPIK3CA | |
| SCHEMBL6315310 | 0.81 | ADORA1 (0.45) | IGF1RPIK3CA | |
| SCHEMBL5885193 | 0.81 | ADORA1 (0.43) | IGF1RPIK3CATNIKKCNH2S1PR1 | |
| SCHEMBL6317900 | 0.78 | IMPDH2 (0.52) | — | |
| SCHEMBL6313033 | 0.77 | ALPL (0.42) | IGF1RPIK3CA | |
| SCHEMBL6312312 | 0.77 | IGF1R (0.49) | IGF1RPIK3CAKCNH2 | |
| SCHEMBL6313126 | 0.77 | HTR3A (0.52) | IGF1RPIK3CA | |
| SCHEMBL31378744 | 0.76 | IGF1R (0.73) | IGF1RPIK3CA | |
| SCHEMBL6318862 | 0.75 | DHFR (0.56) | IGF1RPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | claimed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | claimed |
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | IGF1R 4054/4885PIK3CA 423/4885TNIK 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.